OSI-774 (Erlotinib, Tarceva) in Elderly Patients

Completed · Phase 2

Conditions studied: Non-Small Cell Lung Cancer

In brief

The purpose of this research study is to determine if OSI-774 (Tarceva) is effective in the treatment of non-small cell lung cancer and to further study its side effects. The investigators would also like to estimate disease-related symptom improvement rates using a questionnaire.

Key facts

Study ID

NCT00200395

Run by

Montefiore Medical Center

People needed

30

Starts

2003-07-02

Expected to finish

2007-01-12

Last updated by the study team

2019-12-30

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients must have confirmed non-small cell lung cancer. Age > 65 years Patients must have adequate organ and marrow function

You may not qualify if…

• Patients who have had prior chemotherapy will be excluded. Patients may not be receiving any other investigational agents.

Where it is running

• Beth Israel Medical Center — New York, New York, United States
• New York University — New York, New York, United States
• Albert Einstein Cancer Center — The Bronx, New York, United States
• Montefiore Medical Center- — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.